{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atazanavir%2Fraltegravir", "query": { "intervention": "atazanavir/raltegravir" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=atazanavir%2Fraltegravir&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-29T23:58:02.026Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00666055", "title": "Sex, Aging and Antiretroviral Pharmacokinetics", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "ARV regimen chosen by treating physician", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kristine Patterson, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "FEMALE", "summary": "19 Years and older · Female only" }, "enrollment_count": 11, "start_date": "2008-03", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2012-09-20", "last_synced_at": "2026-09-29T23:58:02.026Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00666055" }, { "nct_id": "NCT00624195", "title": "Clinical Trial of CNS-targeted HAART (CIT2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "FDA Approved Antiretroviral Therapy (see list below)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Diego", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 59, "start_date": "2007-03", "completion_date": "2012-06", "has_results": true, "last_update_posted_date": "2014-04-23", "last_synced_at": "2026-09-29T23:58:02.026Z", "location_count": 5, "location_summary": "San Diego, California • San Francisco, California • Baltimore, Maryland + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00624195" }, { "nct_id": "NCT01384734", "title": "HIV Attachment Inhibitor to Treat Human Immunodeficiency Virus 1 (HIV-1) Infections", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Infection, Human Immunodeficiency Virus" ], "interventions": [ { "name": "BMS-663068 400 mg", "type": "DRUG" }, { "name": "BMS-663068 800 mg", "type": "DRUG" }, { "name": "BMS-663068 600 mg", "type": "DRUG" }, { "name": "BMS-663068 1200 mg", "type": "DRUG" }, { "name": "Raltegravir 400 mg", "type": "DRUG" }, { "name": "Tenofovir 300 mg", "type": "DRUG" }, { "name": "Ritonavir 100 mg", "type": "DRUG" }, { "name": "Atazanavir 300 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ViiV Healthcare", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 254, "start_date": "2011-07-26", "completion_date": "2017-05-12", "has_results": true, "last_update_posted_date": "2018-11-14", "last_synced_at": "2026-09-29T23:58:02.026Z", "location_count": 13, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Coral Gables, Florida + 9 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01384734" }, { "nct_id": "NCT02469246", "title": "Switch Study to Evaluate F/TAF in HIV-1 Infected Adults Who Are Virologically Suppressed on Regimens Containing ABC/3TC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "F/TAF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "ABC/3TC Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" }, { "name": "3rd ARV agent", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 567, "start_date": "2015-06-29", "completion_date": "2019-03-13", "has_results": true, "last_update_posted_date": "2019-10-25", "last_synced_at": "2026-09-29T23:58:02.026Z", "location_count": 34, "location_summary": "Phoenix, Arizona • Beverly Hills, California • La Jolla, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02469246" }, { "nct_id": "NCT02016924", "title": "Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Acquired Immune Deficiency Syndrome (AIDS)", "HIV Infections" ], "interventions": [ { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "Cobicistat", "type": "DRUG" }, { "name": "BR", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "LPV/r", "type": "DRUG" }, { "name": "Third Unboosted Drug", "type": "DRUG" }, { "name": "Cobicistat TOS", "type": "DRUG" }, { "name": "F/TAF TOS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Weeks", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Weeks to 17 Years" }, "enrollment_count": 133, "start_date": "2014-01-16", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-04-21", "last_synced_at": "2026-09-29T23:58:02.026Z", "location_count": 7, "location_summary": "Long Beach, California • Los Angeles, California • Aurora, Colorado + 4 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02016924" }, { "nct_id": "NCT00884793", "title": "Pilot Study on the Effect of Adding Raltegravir +/- a Second Drug on HIV Levels in the Gut", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "raltegravir", "type": "DRUG" }, { "name": "Study NNRTI", "type": "DRUG" }, { "name": "Study PI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 8, "start_date": "2008-09", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2012-07-23", "last_synced_at": "2026-09-29T23:58:02.026Z", "location_count": 2, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00884793" }, { "nct_id": "NCT01332227", "title": "Atazanavir/Ritonavir, Once Daily + Raltegravir, Twice Daily, Switch Study in HIV-1-Infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV, Combination Therapy" ], "interventions": [ { "name": "Atazanavir", "type": "DRUG" }, { "name": "Ritonavir (heat-stable)", "type": "DRUG" }, { "name": "Raltegravir", "type": "DRUG" }, { "name": "Tenofovir/Emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 132, "start_date": "2011-10", "completion_date": "2014-02", "has_results": true, "last_update_posted_date": "2015-02-19", "last_synced_at": "2026-09-29T23:58:02.026Z", "location_count": 8, "location_summary": "Little Rock, Arkansas • Palm Springs, California • San Francisco, California + 5 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Palm Springs", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Daytona Beach", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01332227" }, { "nct_id": "NCT01456962", "title": "Influence of Antiretroviral Regimen on Immune Reconstitution in the Female Genital Tract", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Women's Health", "HIV Infection", "Genital Diseases, Female" ], "interventions": [], "intervention_types": [], "sponsor": "University of Colorado, Denver", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 36, "start_date": "2011-10", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2017-06-09", "last_synced_at": "2026-09-29T23:58:02.026Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT01456962" }, { "nct_id": "NCT00931801", "title": "BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "HIV" ], "interventions": [ { "name": "atazanavir/raltegravir", "type": "DRUG" }, { "name": "atazanavir/tenofovir/emtricitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Community Research Initiative of New England", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2009-12", "completion_date": "2012-03", "has_results": true, "last_update_posted_date": "2017-07-21", "last_synced_at": "2026-09-29T23:58:02.026Z", "location_count": 9, "location_summary": "Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00931801" }, { "nct_id": "NCT02121795", "title": "Switch Study to Evaluate F/TAF in HIV-1 Positive Participants Who Are Virologically Suppressed on Regimens Containing FTC/TDF", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "FTC/TDF", "type": "DRUG" }, { "name": "F/TAF", "type": "DRUG" }, { "name": "Allowed third antiretroviral agent", "type": "DRUG" }, { "name": "FTC/TDF Placebo", "type": "DRUG" }, { "name": "F/TAF Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 668, "start_date": "2014-05-06", "completion_date": "2019-03-01", "has_results": true, "last_update_posted_date": "2020-03-12", "last_synced_at": "2026-09-29T23:58:02.026Z", "location_count": 57, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 40 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Hayward", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02121795" } ] }